LYVE1 and central nervous system cancer: Dao et al. identified and validated a reliable hypoxia-related survival score in IDH-mutant glioma stem cells based on five HRGs (LYVE1, FAM162A, WNT6, OTP, and PLOD), which was significantly related to the survival of patients with glioma [11].